MedTrace Logo

A Crossover Study to Evaluate the Efficacy of Simvastatin in Elevating HDL-C Levels in Patients With Type 2 Diabetes (0733-216)(COMPLETED)

NCT00389896 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2024-08-15

No results posted yet for this study

Summary

The purpose of this study is to see how well simvastatin raises HDL levels in patients with Type 2 Diabetes.

Conditions

  • HDL Cholesterol

Interventions

DRUG

MK0733 / Duration of Treatment: 18 Weeks

DRUG

Comparator: placebo (unspecified) / Duration of Treatment: 18 Weeks

Sponsors & Collaborators

  • Organon and Co

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Merck Sharp & Dohme LLC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-07-26
Primary Completion
2002-10-04
Completion
2002-10-04

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00389896 on ClinicalTrials.gov